Mounjaro Dubai | Tirzepatide Weight Loss Support
Mounjaro Weight Loss Program in Dubai, Guided by MyCare
Mounjaro contains tirzepatide, a dual GIP and GLP-1 receptor agonist. At MyCare, we help suitable patients start safely with doctor assessment, screening, prescription guidance, side-effect support, and progress monitoring.
What is Mounjaro?
Mounjaro is the brand name for tirzepatide, a once-weekly injectable medication that activates two incretin hormone pathways: GIP and GLP-1. These pathways are involved in appetite control, satiety, insulin response, glucagon regulation, and blood sugar control.
Because it works through two receptor pathways, Mounjaro is often described as a dual-action incretin treatment. It may help suitable patients reduce appetite, feel fuller, improve portion control, and support weight reduction when combined with a structured medical program.
Patient-friendly explanation: Ozempic and Wegovy work mainly through GLP-1. Mounjaro works through GLP-1 plus GIP, giving it a dual-pathway mechanism.
How it helps
Mounjaro may support appetite control, satiety, and metabolic health.
- May help reduce frequent hunger signals and make eating feel more controlled.
- May help patients feel satisfied with smaller portions when supported by nutrition guidance.
- Supports blood sugar-related pathways, especially important for patients with metabolic risk.
- Taken once weekly, which may be easier for some patients than daily medication schedules.
Comparison
Mounjaro vs Foundayo vs Wegovy vs Ozempic
The best medication is not simply the “strongest” one. It depends on medical suitability, weight-loss goals, blood sugar profile, tolerance, contraindications, preference for injection or tablet, and doctor recommendation.
| Medication | Active ingredient | How taken | Receptor target |
|---|---|---|---|
|
Mounjaro
| Tirzepatide | Once-weekly injection | Dual GIP + GLP-1 receptor agonist |
|
Foundayo
| Orforglipron | Once-daily oral tablet | GLP-1 receptor agonist |
|
Wegovy
| Semaglutide | Once-weekly injection | GLP-1 receptor agonist |
|
Ozempic
| Semaglutide | Once-weekly injection | GLP-1 receptor agonist |
Mounjaro
Foundayo
Wegovy
Ozempic
Why MyCare
Mounjaro should be managed as a full weight-loss program, not just an injection.
The medication can help with appetite and metabolic control, but patients still need guidance to protect muscle, manage side effects, eat enough protein, stay hydrated, and track progress safely.
Safety first
Who should be assessed carefully before using Mounjaro?
Mounjaro is prescription-only and not suitable for everyone. Your doctor should review your medical history, current medications, weight history, symptoms, and screening results before prescribing.
- Personal or family history of medullary thyroid carcinoma or MEN 2
- History of pancreatitis or significant gastrointestinal disease
- Gallbladder, kidney, liver, thyroid, or endocrine concerns
- Pregnancy, breastfeeding, or plans to become pregnant
- Diabetes medication use, especially insulin or sulfonylureas
- Previous severe reaction to GLP-1 or incretin-based medication
Suggested pre-treatment screening
All tests available as part of MyCare Health Snapshot™
How to start Mounjaro safely with MyCare
Eligibility call
We understand your goals, medical history, current weight challenges, and whether a doctor assessment is appropriate.
Doctor consultation
A licensed doctor reviews your risks, medication history, and whether Mounjaro or another pathway is suitable.
Screening
Complete recommended labs and Health Snapshot™ to create a safer baseline before treatment.
Ongoing support
Track tolerance, side effects, appetite, weight, body composition, hydration, protein intake, and follow-up needs.
Mounjaro Frequently Asked Questions
Is Mounjaro the same as Ozempic or Wegovy?
No. Mounjaro contains tirzepatide and targets two incretin receptors: GIP and GLP-1. Ozempic and Wegovy contain semaglutide and target the GLP-1 receptor.
Why is Mounjaro called dual-action?
Mounjaro is called dual-action because tirzepatide activates both GIP and GLP-1 receptors. These pathways are involved in appetite, satiety, glucose regulation, and insulin response.
Is Mounjaro an injection?
Yes. Mounjaro is given as a once-weekly subcutaneous injection. A healthcare provider should guide proper use, dose escalation, storage, and side-effect monitoring.
Can Mounjaro be used for weight loss?
Mounjaro may support weight reduction in suitable patients, but treatment should be medically assessed and prescribed. The right pathway depends on your health profile, goals, medical history, and doctor recommendation.
Do I need screening before starting Mounjaro?
Yes. Screening helps identify safety concerns, metabolic risks, kidney and liver status, diabetes risk, thyroid considerations, and other factors that may affect suitability.
Is medication enough?
No. Mounjaro can help reduce appetite and improve metabolic control, but better results require nutrition structure, protein guidance, hydration, movement, sleep review, and ongoing monitoring.
Book with MyCare
Find out if Mounjaro is suitable for you.
Speak with MyCare about doctor assessment, screening, prescription requirements, dose guidance, and the right medical weight-loss pathway for your goals.
Prescription treatments require consultation, screening, and clinician approval.